Show simple item record

dc.contributor.authorJayson, Gordon C
dc.contributor.authorHarris, John
dc.date.accessioned2009-07-09T12:25:18Z
dc.date.available2009-07-09T12:25:18Z
dc.date.issued2006-04
dc.identifier.citationHow participants in cancer trials are chosen: ethics and conflicting interests. 2006, 6 (4):330-6 Nat. Rev. Canceren
dc.identifier.issn1474-175X
dc.identifier.pmid16557284
dc.identifier.doi10.1038/nrc1842
dc.identifier.urihttp://hdl.handle.net/10541/73081
dc.description.abstractThe development of new drugs for cancer is extremely complex and expensive, and poses ethical problems. In this article we will review issues in clinical trials for cancer drugs that will cast new light on the doctor-patient relationship and their interaction with industry, the health service, academic and administrative organizations. We show that the Declaration of Helsinki cannot be applied to cancer trials as it is currently written, that patients do not and perhaps cannot give fully informed consent to participate, and that the results of clinical trials do not translate into daily practice in a way that patients might expect.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshClinical Trials as Topic
dc.subject.meshConflict of Interest
dc.subject.meshEthics, Medical
dc.subject.meshHumans
dc.subject.meshNeoplasms
dc.subject.meshPatient Selection
dc.titleHow participants in cancer trials are chosen: ethics and conflicting interests.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, University of Manchester, Department of Medical Oncology, Christie Hospital, Withington, Manchester M20 4BX, UK. Gordon.Jayson@christie-tr.nwest.nhs.uken
dc.identifier.journalNature Reviews. Canceren
html.description.abstractThe development of new drugs for cancer is extremely complex and expensive, and poses ethical problems. In this article we will review issues in clinical trials for cancer drugs that will cast new light on the doctor-patient relationship and their interaction with industry, the health service, academic and administrative organizations. We show that the Declaration of Helsinki cannot be applied to cancer trials as it is currently written, that patients do not and perhaps cannot give fully informed consent to participate, and that the results of clinical trials do not translate into daily practice in a way that patients might expect.


This item appears in the following Collection(s)

Show simple item record